← Back to Patent Explorer
US5081030A Expired / Lapsed US ⏱️ 0.0 years remaining

Release of cells from affinity matrices

Assignee: Johns Hopkins University
•
Filing: 1989-04-25
•
Granted: 1992-01-14
•
Expires: 2009-04-25
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The present invention comprises a process for release from the cell-receptor complex of positively selected cells in viable, functional condition, where a ligand involved in the particular receptor-ligand interaction utilized for the affinity purification is selectively attacked by one or more degradative enzymes specific for that ligand. A resulting cell suspension can be obtained substantially free of receptor material. This invention, in one embodiment, contemplates a method for positive stem cell selection, utilizing anti-MY10 and immunomagnetic microspheres to isolate CD34-positive marrow cells and employing an enzyme to release micropheres from the isolated CD34-positive cells. Reproducible enzymatic cleaving of immunomagnetic microspheres from MY10-positive cells can be achieved by brief treatment of the preparation with papain or chymopapain. The isolated CD34-positive cells are particularly desirable for bone marrow transplantation.

Inventors

  • 👤 Curt I. Civin

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-06 03:53
CPC Classifications
C; C12; C12Q; C12Q1/00; C12Q1/02; C12Q1/24; A; A61; A61K; A61K35/00; A61K35/12; A61K35/28

Claims Analysis

Total Claims: 7
Claim 1
Independent Claim 31 words
A method for releasing animal cells bound to antibodies specific for the MY10 epitope which comprises treating the antibody bound animal cells with chymopapain and separating viable cells from said antibodies.
Claim 2
Independent Claim 31 words
A method for releasing animal cells bound to antibodies specific for the MY10 epitope which comprises treating the antibody bound animal cells with chymopapain and separating viable cells from said antibodies.
Claim 3
Dependent Claim 16 words
The method of claim 1 in which the antibody is attached to an insoluble affinity matrix.
Claim 4
Dependent Claim 12 words
The method of claim 2 in which the matrix comprises immunomagnetic microspheres.
Claim 5
Dependent Claim 13 words
The method of claim 1 in which the antibody is a fluorescent-labeled antibody.
Claim 6
Independent Claim 58 words
A method for the purification of lymphohematopoietic precursor cells comprising: (a) treating a population of human cells containing CD34-positive cells with an affinity material comprising a monoclonal antibody specific for MY10 epitope; (b) separating antibody-bound cells from unbound cells; (c) treating the antibody-bound cells with chymopapain; and (d) separating non-cellular materials from the cells released by enzyme treatment.
Claim 7
Independent Claim 58 words
A method for the purification of lymphohematopoietic precursor cells comprising: (a) treating a population of human cells containing CD34-positive cells with an affinity material comprising a monoclonal antibody specific for MY10 epitope; (b) separating antibody-bound cells from unbound cells; (c) treating the antibody-bound cells with chymopapain; and (d) separating non-cellular materials from the cells released by enzyme treatment.

References Cited (Backward Citations)

US4714680A Cited
US4714680B1 Cited
US4814433A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1995-01-13 1995-07-15 1996-01-14 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1999-01-13 1999-07-15 2000-01-14 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2003-01-13 2003-07-15 2004-01-14 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag